{
  "id": 8274775,
  "title": "AbCellera and Recursion Pharmaceuticals: two AI-drug stocks, two different stories",
  "url": "https://urgent.news/2026/09/18/abcellera-and-recursion-pharmaceuticals-two-ai-drug-stocks-two",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-18T17:04:28.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/abcellera-and-recursion-pharmaceuticals-two-aidrug-stocks-two-different-stories-93CH-4907720"
  },
  "original_language": "en",
  "account": "AbCellera and Recursion Pharmaceuticals, two AI-driven biotech companies, present contrasting investment opportunities as of September 18, 2026. While both lack profitability, their revenue forecasts and valuation metrics offer distinct perspectives.\n\nRecursion Pharmaceuticals (RXRX) exhibits more promising valuation metrics. It trades near its fair value of $3.66, compared to a higher fair value of $3.94 for AbCellera (ABCL). RXRX's price-to-book ratio stands at 2.2x, significantly lower than ABCL's 4.5x. Furthermore, RXRX has garnered a strong consensus upside of +97.7% from analysts despite a negative free cash flow yield of -17.9%. The market has already priced in considerable pessimism following a -28.2% year-over-year decline. Conversely, ABCL appears overvalued, with its fair value model indicating a -44.4% downside from the current price of $12.53. This suggests a market valuation approximately double its intrinsic value estimate of $6.96. Cantor Fitzgerald's $11 price target, set on July 17, is also below the current price, supporting this valuation assessment.\n\nABCL's bullish outlook hinges on a single binary catalyst: Phase 2 data for its anti-NK3R antibody, ABCL635, aimed at treating menopausal vasomotor symptoms, expected in Q3 2026. Analysts at Cantor Fitzgerald anticipate a potential 50%+ upside if the data turns out positively. However, this scenario resembles a lottery ticket rather than a solid valuation call. ABCL's weekly RSI of 74, coupled with a CCI of 229.9 and a developing bearish Harami candlestick pattern on the daily chart, signals short-term exhaustion. While the trend remains strong, with an ADX of 34 on the weekly chart, momentum indicators are nearing extended levels.\n\nThe widening price ratio between RXRX and ABCL, with RXRX up 170% and ABCL down -28%, may indicate a mean reversion opportunity. However, ABCL's bullish narrative seems premature, with the stock price ahead of improved fundamentals. For a pairs trade, a long RXRX short ABCL structure could be a coherent strategy, but careful sizing of the ABCL short position is advisable in anticipation of the pivotal Phase 2 data. It is essential to remember that historical data on Pro+ plan is limited to the past 10 years, and this article has been AI-generated and reviewed by an editor.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}